Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
Related to this article
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
2
Positive Topline Results From Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
3
Podcast: Diego Regalado, MD, on Culturally Responsive Psychiatric Care for Hispanic Patients
4
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
5